Design and analysis of non-inferiority mortality trials in oncology

Statistics in Medicine

Volumn 22, Issue 2, 2003, Pages 239-264

  Rothmann, Mark ^a   Li, Ning ^a   Chen, Gang ^a   Chi, George Y H ^a   Temple, Robert ^a   Tsou, Hsiao Hui ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Active control trials; Non inferiority trials

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; PLACEBO;

ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; DATA ANALYSIS; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MEDICAL ETHICS; META ANALYSIS; METHODOLOGY; MORBIDITY; ONCOLOGY; SAMPLE SIZE; STATISTICAL ANALYSIS; SURVIVAL; TIME;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; CONTROLLED CLINICAL TRIALS; DEOXYCYTIDINE; HUMANS; RESEARCH DESIGN; STATISTICS;

EID: 0037472909     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1400     Document Type: Article

References (16)

1. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Journal of the American Medical Association 2000; 284:3043-3045.
2. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). E-10: Guidance on choice of control group in clinical trials. Federal Register 64:51767-51780.
3. Temple R, Ellenberg SS. Placebo controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 2000; 133:455-463.
4. Ellenberg SS, Temple R. Placebo controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Annals of Internal Medicine 2000; 133:464-470.
5. Rothman KJ, Michels KB. The continued unethical use of placebo controls. New England Journal of Medicine 1994; 331:394-398.
6. Hauck W, Anderson S. Some issues in the design and analysis of equivalence trials. Drug Information Journal 1999; 33:109-118.
7. Holmgren EB. Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained. Journal of Biopharmaceutical Statistics 1999; 9(4):651-659.
8. Simon R. Bayesian design and analysis of active control clinical trials. Biometrics 1999; 55:484-487.
9. Koch GG, Tangen CM. Nonparametric analysis of covariance and its role in non-inferiority clinical trials. Drug Information Journal 1999; 33:1145-1159.
10. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug Information Journal 2001; 35:435-449.
11. Wiens B. Choosing an equivalence limit for non-inferiority or equivalence studies. Controlled Clinical Trials 2002; 1-14.
12. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998; 17:2815-2834.
13. DerSimonian R, Laird N. Meta-analyses in clinical trials. Controlled Clinical Trials 1986; 7:177-188.
14. FDA Medical-Statistical review for Xeloda (NDA 20-896) dated 23 April, 2001.
15. Fleming TR, Harrington D. Counting Processes and Survival Analysis. Wiley: New York; 1991.
16. Read CB. Fieller's theorem. In Encyclopedia of Statistical Sciences, Kotz S, Johnson N (eds). Wiley: New York, 1983; 86-88.